Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (489)	3/2/2005 2:38:52 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

Larry was also extremely positive about what was, at that time called Maxamine, all the way into the first FDA disaster. That taught me not to draw too far-reaching conclusions from the level of optimism in a CEO presentation. But with the new facts presented over the last couple of days, it becomes increasingly difficult to come up with a scenario about what might have caused this trial to produce extended survival, apart from a treatment effect from Xyotax. More or less the only thing left is the fact that earlier comparative trials were not specifically designed to treat PS2 patients and these patients were just a small subgroup in a larger trial. Maybe that had a negative effect on the outcome, as they might not have received optimal treatment. But that is a relatively far-fetched argument. Bianco sounds extremely confident and seems to have a big pharma agreement already wrapped up and ready for presentation. The only remaining question seems to be if this will happen this week or next. Erik